Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
about
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and ImmunostimulatorsGas Vesicle Nanoparticles for Antigen DisplayNanoparticulate adjuvants and delivery systems for allergen immunotherapyA Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human PrimatesVault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of miceAntibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.Laser vaccine adjuvants. History, progress, and potentialpH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine modelAdvances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsTowards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain.Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitisDesign of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccinationPreparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study.Multiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in miceHaloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine developmentA polymer/oil based nanovaccine as a single-dose immunization approach.Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactionsIn vivo and in vitro characterization of the immune stimulating activity of the Neisserial porin PorBAn overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesThe concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae.The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensA Highly Effective Component Vaccine against Nontyphoidal Salmonella enterica Infections.Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles.A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivoThe effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cellsChitosan and Sodium Alginate Combinations Are Alternative, Efficient, and Safe Natural Adjuvant Systems for Hepatitis B Vaccine in Mouse Model.Engineering nano- and microparticles to tune immunityThe administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.Delivery systems: a vaccine strategy for overcoming mucosal tolerance?Recombinant vaccines and the development of new vaccine strategies.Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.Liposome-based cationic adjuvant formulations (CAF): past, present, and future.Chitosan-based systems for the delivery of vaccine antigens.Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice.Archaeal lipid mucosal vaccine adjuvant and delivery system.Biomimetic nanoparticles: preparation, characterization and biomedical applications.
P2860
Q26765446-AB16EA98-91D1-42DD-B3CB-9367D6123413Q26782563-5957EE42-0F02-4520-BB79-A8D017F73154Q26825418-BFF6B4E4-50F4-46F5-BCD4-98E7660C7DC5Q27116692-7C64229C-C996-4A1C-A7B8-B0619A4063EAQ28727249-A04E90F0-6757-4AA4-8BCD-362FE3580DD8Q30397437-7124ED65-8003-40CA-94E3-9A218DDF1128Q30413501-15E0FDDC-C936-4C61-97EB-EFD77D398161Q33703757-EB88CD39-A050-4E36-9EFA-CE577498CBC9Q33710976-C4F1A924-D966-4E0F-8E95-FD224320ED9BQ33721641-83BF4EA2-13AD-49AE-91E8-BC8D47E55A78Q33946847-B382D653-FBDA-4B15-82FB-DB738F2DD5DBQ34053031-B991BE6A-EA87-4D17-A0AB-0B2AF6348611Q34074750-17476999-949C-4AC4-95F9-AFCE8ECB6CB4Q34093684-25E9D8C4-2618-410D-B506-2946A2E23740Q34140252-491C71AE-9A7C-4D8E-9CDD-76A135BBE706Q34515009-11A1F053-6794-4549-AE30-04D0E5526986Q34685874-8C955404-1A39-4566-9283-FAF32C4E0290Q34802680-DBD52D9B-568E-49CE-BF9B-D524B1000AA9Q34976001-CDACDDC7-5842-4995-964E-1E3F8E641625Q35070034-BAB9A855-6A1A-4F6A-9DA5-FA5416D0C7B7Q35100779-FA979E96-FDC0-40C5-938C-BEFE2E9CB1E9Q35142944-BAEDE418-821E-4ACD-9231-07B88C41B691Q35191903-E5E61809-8541-42BC-AE5D-8EB9C570D333Q35812875-A2BABAA7-16DB-4413-953F-660A9A4B6718Q36143656-249D00A2-34EC-4B99-AC77-4A06E394FC29Q36160348-EF3596FD-08EA-4B6F-98EC-9B995326AD77Q36452968-6242AC83-1CBE-4C79-8574-7C8E97D72D49Q36553255-828DBB17-1038-423C-BD21-8849998071BAQ37132243-973F2A06-6A1B-4190-BA80-B6557178BF01Q37205125-072AE95C-508E-4298-A331-7AF5F322D0F8Q37294444-EE8A0E6B-ADA1-493B-89C0-0FE765A89872Q37332628-DB792BA0-BA9D-464C-8BCB-BB41E5889D41Q37354182-9C9B4D86-B445-4289-AFE4-34C754F7E04AQ37370940-EE929283-2E7F-4E2E-AD6A-EF35D2782909Q37371036-FD2196C4-6FEE-4D7E-AFE7-7F00000D4459Q37514354-2F57678F-BF68-47E2-9588-DC38782683DCQ37524050-F7B01CBF-A8D0-485E-9A58-53C7E5864B38Q37539243-5D15CE0A-A1CE-422F-B722-7200E102547EQ37724863-BDEE9A09-AC6C-4A9D-995C-8867D9804CADQ37750489-5E016E81-372B-4BEC-BAF5-E84B272A2BB3
P2860
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@en
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@nl
type
label
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@en
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@nl
prefLabel
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@en
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@nl
P2093
P1476
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
@en
P2093
Afzal R Mohammed
Sarah E McNeil
Vincent W Bramwell
Yvonne Perrie
P304
P356
10.1016/J.IJPHARM.2008.04.036
P407
P50
P577
2008-04-30T00:00:00Z